CURRICULUM VITAE Gerald Louis Andriole, Jr., M.D. Address ...

99. Albala, D.M., Andriole, G.L., Davis, B.E., Eure, G.R., Kabalin, J.N., Lingeman, J.E., Nuzzarello, J.,
Risk, I.: Transurethral Microwave Thermotherapy Using the TherMatrx TMX-2000: Durability Exhibited
in a Study Comparing TUMT with a Sham Procedure in Patients with Benign Prostatic Hyperplasia. 98 th
Annual Meeting of the American Urological Association, Chicago, IL, April-May , 2003.
100. Sakoda, L.C., Hayes, R.B., Huang, W.Y., Peters, U., Chatterjee, N., Andriole, G.L., Church, T.R., Chia,
D., Hoover, R.N., and Hsing, A.W.: Use of aspirin and ibuprofen in relation to prostate cancer risk.
Annual Meeting of the American Association for Cancer Research, 2004.
101. Andriole, G.L., Pinsky, P.F., Levin, D.L., Gelmann, E.P., Crawford, E.D., Reding, D., Prorok, P.C. and
Gohagan, J.F.: The Prostate. Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: Biopsy Rates
and Cancer Characteristics of Initial (T0) Screen (II). 99 th Annual Meeting of the American Urological
Association, San Francisco, CA, May, 2004.
102. Andriole, G.L., Roehrborn, C., Schulman, C., Slawin, K., Somerville, M, and Rittmaster R.: Effect of
dutasteride on the incidence of prostate cancer (CaP) in men with benign prostatic hyperplasia. 99 th
Annual Meeting of the American Urological Association, San Francisco, CA, May, 2004.
103. Andriole, G.L., Humphrey, P., Ray, P., Gleave, M.E., Trachtenberg, J., Thomas, L.N., Lazier, C.B. and
Rittmaster, R.R.: Effect of the Dual 5α-Reductase inhibitor Dutasteride on Markers of Regression in
Prostate Cancer. 99 th Annual Meeting of the American Urological Association, San Francisco, CA, May,
2004.
104. Schulman, C. and Andriole, G.L., Effect of the dual 5α reductase inhibitor dutasteride on the detection of
prostate cancer in men with BPH in a four-year study, European Association of Urology, 2004
(submitted).
105. Cross, A.J., Peters, U., Hayes, R.B., Andriole, G.L., Reding, D., and Sinha, R.: The heterocyclic amine,
PhIP, found in meat cooked at high temperatures may increase prostate cancer risk. American Society of
Clinical Oncology, 2004.
106. Andriole, G.L., Noble, W.D., Lucia, M.S., Kusek, J.W., Roehrborn, C.G. for the MTOPS Research
Group: Baseline body mass index and the development of prostate cancer in the Medical Therapy of
Prostatic Symptoms (MTOPS) Trial. Annual Meeting of the American Urological Association, San
Antonio, TX, May, 2005.
107. Andriole, G.L., Noble, W.D., Slawin, K.M., Crawford, E.D., Lucia, M.S., Kusek, J.W., Roehrborn, C.G.
for the MTOPS Research Group: Distribution of Gleason scores among men discovered to have prostate
cancer in the Medical Therapy of Prostatic Symptoms (MTOPS) Trial. Annual Meeting of the American
Urological Association, San Antonio, TX, May, 2005.
108. Albala, D.M., Andriole, G.L., Davis, B., Eure, G., Kabalin, J.N., Lingeman, J.E., and Nuzzarello, J.:
Transurethral microwave thermotherapy using the TherMatrx TMX-2000; long-term results in a study
comparing TUMT with a sham procedure in patients with benign prostatic hyperplasia. Annual Meeting
of the American Urological Association, San Antonio, TX, May, 2005.
109. Hayes, R.B., Pinsky, P., Riley, T., Prorok, P., Andriole, G.L., and Crawford, E.D.: Prostate cancer
incidence following a negative screening exam. American Association for Cancer Research.
110. Grubb RL, III, Levin DL, Pinsky PF, Mabie J, Riley TL, Greenlee R, Urban DA, Ragard LR, Crawford
ED and Andriole, GL: Body Mass Index and Impact on PSA Screening and Prostate Cancer Detection in
the PLCO Trial. Annual Meeting of the American Urological Association, Atlanta GA, May, 2006.
19